Department of Infectious Diseases, Leiden University Medical Center, Building 1, Albinusdreef 2, 2333ZA, Leiden, The Netherlands.
Department of Infectious Diseases, Leiden University Medical Center, Building 1, Albinusdreef 2, 2333ZA, Leiden, The Netherlands.
Trends Immunol. 2022 May;43(5):355-365. doi: 10.1016/j.it.2022.03.002. Epub 2022 Mar 31.
The essentially monomorphic human antigen presentation molecule HLA-E is an interesting candidate target to enable vaccination irrespective of genetic diversity. Predictive HLA-E peptide-binding motifs have been refined to facilitate HLA-E peptide discovery. HLA-E can accommodate structurally divergent peptides of both self and microbial origin. Intracellular processing and presentation pathways for peptides by HLA-E for T cell receptor (TCR) recognition remain to be elucidated. Recent studies show that, unlike canonical peptides, inhibition of the transporter associated with antigen presentation (TAP) is essential to allow HLA-E antigen presentation in cytomegalovirus (CMV) infection and possibly also of other non-canonical peptides. We propose three alternative and TAP-independent MHC-E antigen-presentation pathways, including for Mycobacterium tuberculosis infections. These insights may help in designing potential HLA-E targeting vaccines against tumors and pathogens.
人类主要同种异型抗原呈递分子 HLA-E 是一个有趣的候选靶点,可实现不论遗传多样性如何均可接种疫苗。已经对预测性 HLA-E 肽结合基序进行了改进,以促进 HLA-E 肽的发现。HLA-E 可以容纳源自自身和微生物的结构上不同的肽。HLA-E 用于 T 细胞受体 (TCR) 识别的细胞内加工和呈递途径仍有待阐明。最近的研究表明,与经典肽不同,抑制抗原呈递相关转运蛋白 (TAP) 对于允许巨细胞病毒 (CMV) 感染中的 HLA-E 抗原呈递以及可能还有其他非经典肽的呈递是必不可少的。我们提出了三种替代的、不依赖 TAP 的 MHC-E 抗原呈递途径,包括结核分枝杆菌感染。这些见解可能有助于设计针对肿瘤和病原体的潜在 HLA-E 靶向疫苗。